NORTH CHICAGO, Ill. , July 1, 2016 /PRNewswire/ --  AbbVie (NYSE: ABBV) will announce its second-quarter 2016 financial results on Friday, July 29, 2016 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern).

NORTH CHICAGO, Ill. , June 16, 2016 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share.  The cash dividend is payable Aug. 15, 2016 to stockholders of record at the close of business on July 15, 2016 .

- AbbVie is dedicated to delivering innovative new therapies that significantly advance the standard of care - AbbVie's late- and early-stage pipelines will drive long-term sustainable performance - AbbVie's late-stage pipeline has the potential to deliver more than 20 new medicines or indications

NORTH CHICAGO, Ill. , May 31, 2016 /PRNewswire/ --  AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 37 th Annual Global Healthcare Conference on Thursday, June 9, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at

NORTH CHICAGO, Ill. , May 12, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer session at 1:00 p.m. Central time .

NORTH CHICAGO, Ill. , April 29, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2016 Global Health Care Conference on Thursday, May 12, 2016 . Bill Chase , executive vice president and chief financial officer, will participate in a question and answer

- Reports First-Quarter Adjusted Diluted EPS of $1.15, Up 22.3 Percent; GAAP Diluted EPS of $0.83 - Delivers First-Quarter Net Revenues of $5.96 Billion, an Increase of 22.4 Percent Over First-Quarter 2015 on an Operational Basis; Reported Net Revenues Increased 18.2 Percent - Delivers Adjusted

- Rovalpituzumab tesirine (Rova-T) is a biomarker-specific antibody drug conjugate targeting cancer stem cell protein DLL3 - Compelling data on Rova-T was presented at the European Society of Medical Oncology demonstrating overall response rates of 44 percent in DLL-expressing small cell lung

- Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71 - AbbVie to Receive the Right to License Probody Drug Conjugates for up to Two Additional Undisclosed Targets - CytomX to Receive $30 Million Upfront Payment NORTH CHICAGO, Ill.

NORTH CHICAGO, Ill. and BREDA, The Netherlands and GHENT, Belgium , April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic